The American pharmaceutical group Eli Lilly published on Thursday the results of a new clinical study confirming that its drug Tirzepatide, currently approved in the United States only against diabetes, helps with weight loss, reports AFP.
Tirsepatide mimics a gastrointestinal hormone. PHOTO Shutterstock (Archive)
These results pave the way for possible authorization of this drug in the near future by the Food and Drug Administration (FDA) for people suffering from obesity, writes Agerpres.
The study was conducted on a sample of over 900 overweight or obese participants diagnosed with type 2 diabetes (the most common type). The medicine is administered only once a week in the form of an injection.
People who received the highest dose lost an average of 15.6 kilograms (15.7% reduction in body weight) over a period of about a year and a half (72 weeks).
Side effects were generally gastrointestinal problems (nausea, diarrhea, vomiting).
Thanks to these results, Eli Lilly plans to finalize its application for approval of the drug for obese and overweight patients “in the coming weeks” and “a regulatory decision is expected by the end of 2023“.
A first clinical study, the results of which were published in a scientific journal in June 2021 and which targeted obese and overweight people but did not suffer from diabetes, demonstrated an even more important weight loss, of the order of 21 %.
Tirzepatide mimics a gastrointestinal hormone (GLP-1) that activates receptors in the brain that play a role in appetite regulation.
The drug is marketed under the name Mounjaro for people with type 2 diabetes after an FDA approval in May 2022.
But certain American doctors are already prescribing it outside the marketing authorization, recommending it to people who want to lose weight, even though they don’t have diabetes.
About 40% of adults in the US are obese
In the United States, approximately 40% of adults are obese.
Treatments that use GLP-1 analogs represent a real hope for many specialists, as they cause much more significant weight loss than drugs available to date.
There is also considerable commercial stake for pharmaceutical companies: According to Morgan Stanley, the global market for obesity treatments could reach $54 billion by 2030.
The manufacturer Novo Nordisk is already marketing a new treatment of this type in the United States, called Wegovy and approved by the FDA against obesity in June 2021.
Its approved anti-diabetic counterpart, Ozempic, which uses the same molecule (semaglutide), has recently faced periodic stockouts after making headlines on social media for its weight-loss properties.
However, medical experts are concerned about the risk of people who are not clearly overweight using it to lose a few pounds.
In the United States, there is also a problem of access to these extremely expensive new drugs (about $1,000 per month), because they are rarely reimbursed by health insurance companies. At the same time, they must be taken long-term, otherwise the patient risks gaining weight again when the treatment is stopped.
2023-04-27 17:50:24
#Efficacy #confirmed #obesity #treatment #STUDY #truth
